What does Big Pharma Split Corp. do?

Big Pharma Split Corp. (PRM.TO) operates in the Asset Management industry within the Financial Services sector. Full company description, peers, and segment breakdown are on the page above.

What is PRM.TO's market cap?

Big Pharma Split Corp. (PRM.TO) has a market capitalization of approximately $20.8 million, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does PRM.TO pay a dividend?

Yes — Big Pharma Split Corp. (PRM.TO) pays a dividend monthly, with a trailing-twelve-month yield of 7.74%. Full distribution history, payout ratios, and growth rates are on the Dividend tab.

Is PRM.TO profitable?

Big Pharma Split Corp. (PRM.TO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

PRM.TO

Big Pharma Split Corp.

TSX·Asset Management · Financial Services

C$15.98C$0.03+0.19%

Market capC$20.84M·Market closed·Aug 26 7:32 PM UTC

Price Chart

C$15.98+C$0.03 (+0.19%)today

+5.83%CAGR +1.14%

Select date range

FromTo

Nov 24, 2017Aug 27, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

DividendDividend Tab

Dividend Yield (FWD)7.74%

Annual Dividend (FWD)C$1.24

Dividend Growth (5Y)+0.0%

Dividend Safety—

Payout Ratio—

FCF Payout Ratio—

Most Recent DividendC$0.103

Ex-Dividend DateJul 31

Payment DateAug 6

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)+30.5%

EPS Growth (5Y)—

Next Earnings Date—

Last Report DateDec 30

Reported vs Estimate−C$1.54

Earnings Surprise—

FinancialsFinancials Tab

Revenue−C$1.03M

Net IncomeC$4.40M

Net Margin−425.9%

Operating Cash Flow−C$40.59K

Capital ExpendituresC$3.00

Free Cash Flow−C$40.59K

Return on Equity24.1%

Return on Invested Capital16.5%

Net CashC$18.05M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for PRM.TO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how PRM.TO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PRM.TO and 80,000+ other tickers.

About Big Pharma Split Corp.

Big Pharma Split Corp, a closed-end equity investment fund, was established on September 15, 2017, and maintains its domicile in Canada. Overseen by Harvest Portfolios Group Inc., the fund concentrates its investments primarily within the pharmaceutical sector, targeting publicly traded companies across the United States.

CEO: Louis Michael Kovacs
Sector: Financial Services
Industry: Asset Management
Exchange: TSX
Website: www.harvestportfolios.com/closed-end-funds/big-pharma-split-corp

Peers

Elysee Development Corp.

Cap

C$17.2M

NRC.V

Nations Royalty Corp.

Cap

C$149.0M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About PRM.TO

What does Big Pharma Split Corp. do?: Big Pharma Split Corp. (PRM.TO) operates in the Asset Management industry within the Financial Services sector. Full company description, peers, and segment breakdown are on the page above.
What is PRM.TO's market cap?: Big Pharma Split Corp. (PRM.TO) has a market capitalization of approximately $20.8 million, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does PRM.TO pay a dividend?: Yes — Big Pharma Split Corp. (PRM.TO) pays a dividend monthly, with a trailing-twelve-month yield of 7.74%. Full distribution history, payout ratios, and growth rates are on the Dividend tab.
Is PRM.TO profitable?: Big Pharma Split Corp. (PRM.TO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.